Please Wait.....
Report
North America Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
Market Report I 2022-11-18 I 193 Pages I The Insight Partners
The glycomic therapeutics market in North America is expected to grow from US$ 42.55 billion in 2022 to US$ 100.79 billion by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.
Application in Treatment of Broad Range of Disorders Drives Market Growth
Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.
For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.
In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.
In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.
Market Overview
The North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US held the largest share of the North America glycomic therapeutics market in 2022. The increasing demand in the region, followed by rising research and development activities by various major firms, rising number of investments in glycomic therapeutics research, and growing awareness about glycomic therapeutics, is expected to drive the overall glycomic therapeutics market during the forecast period.
North America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)
North America Glycomic Therapeutics Market Segmentation
TheNorth America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
Based on class, the North America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the North America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the North America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the North America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); HalozymeTherapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Lt. are the leading companies operating in the glycomic therapeutics in North America.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Glycomic Therapeutics Market - By Class
1.3.2 North America Glycomic Therapeutics Market - By Structures
1.3.3 North America Glycomic Therapeutics Market - By Indications
1.3.4 North America Glycomic Therapeutics Market - By Mode of Action
1.3.5 North America Glycomic Therapeutics Market - By Country
2. North America Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Glycomic Therapeutics Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert Opinion
5. North America Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market- North America Analysis
6.1 North America Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.1 North America: Glycomic Therapeutics Market, 2019-2028 (US$ Million)
7. North America Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
7.1 Overview
7.2 North America Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 North America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 North America Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 North America Synthetic - Revenue and Forecast to 2028 (US$ Million)
8. North America Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
8.1 Overview
8.2 North America Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 North America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 North America Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 North America Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 North America Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 North America Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher's diseases
8.7.1 Overview
8.7.2 North America Gaucher's diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 North America MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 North America Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer's
8.10.1 Overview
8.10.2 North America Alzheimer's Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 North America Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 North America Others Revenue and Forecast to 2028 (US$ Million)
9. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
9.1 Overview
9.2 North America Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 North America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
9.2.1.1 North America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
9.2.1.2 North America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
9.2.1.3 North America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
9.2.1.4 North America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 North America Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 North America Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.3.2 North America Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.4.4 Oseltamivir
9.4.4.1 Overview
9.4.4.2 North America Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 North America Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 North America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 North America Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 North America Heparin - Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 North America Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 North America Laronidase - Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 North America Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 North America Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 North America Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 North America Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 North America Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.4.2 North America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 North America Acarbose - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 North America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 North America Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)
10. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
10.1 Overview
10.2 North America Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 North America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 North America Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 North America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 North America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 North America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 North America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 North America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 North America Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 North America Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. North America Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
11.1 North America: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.3 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.1 Overview
11.1.3.1.2 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.3 US: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.3.1.4 US: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.3.1.4.1 US: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.3.1.4.2 US: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.3.1.4.3 US: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.3.1.4.4 US: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.3.1.5 US: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.3.1.6 US: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.3.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.1 Overview
11.1.3.2.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.3 Canada: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.3.2.4 Canada: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.3.2.4.1 Canada: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.3.2.4.2 Canada: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.3.2.4.3 Canada: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.3.2.4.4 Canada: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.3.2.5 Canada: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.3.2.6 Canada: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.3.3 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.1 Overview
11.1.3.3.2 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.3 Mexico: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.3.3.4 Mexico: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.3.3.4.1 Mexico: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.3.3.4.2 Mexico: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.3.3.4.3 Mexico: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.3.3.4.4 Mexico: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.3.3.5 Mexico: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.3.3.6 Mexico: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
12. Glycomic Therapeutics Market -Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 BioMarin Pharmaceutical Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Genzyme Corporation (Sanofi)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Halozyme Therapeutics, Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Alzheon, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GlaxoSmithKline plc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market
LIST OF TABLES
Table 1. North America Glycomic Therapeutics Market, Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Glycomic Therapeutics Market, by C lass - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 4. North America Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 5. North America Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 6. North America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 7. North America Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 8. North America Glycomic Therapeutics Market, by Others- Revenue and Forecast to 2028 (USD Million)
Table 9. North America Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 10. US Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (USD Million)
Table 11. US Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 12. US Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 13. US Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 14. US Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 15. US Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (USD Million)
Table 16. US Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 17. US Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 18. Canada Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (USD Million)
Table 19. Canada Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 20. Canada Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 21. Canada Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 22. Canada Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 23. Canada Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (USD Million)
Table 24. Canada Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 25. Canada Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 26. Mexico Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 27. Mexico Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 28. Mexico Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 29. Mexico Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 30. Mexico Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 31. Mexico Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 32. Mexico Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 33. Mexico Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 34. Organic Developments in the Glycomic Therapeutics Market
Table 35. Inorganic Developments in the Glycomic Therapeutics Market
Table 36. Glossary of Terms in Glycomic Therapeutics Market
LIST OF FIGURES
Figure 1. North America Glycomic Therapeutics Market Segmentation
Figure 2. North America Glycomic Therapeutics Market, By Country
Figure 3. North America Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in North America Glycomic Therapeutics Market
Figure 5. Canada is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. North America Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. North America Glycomics market - Revenue Forecast And Analysis - 2020- 2028
Figure 9. North America Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. North America Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. North America Synthetic - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. North America Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. North America Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. North America Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. North America Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. North America Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. North America Gaucher's diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. North America MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. North America Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. North America Alzheimer's Revenue and Forecasts to 2028 (US$ Million)
Figure 21. North America Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. North America Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. North America Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. North America Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. North America Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. North America Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. North America Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. North America Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. North America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. North America Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. North America Heparin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. North America Hyaluronan (HA) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. North America Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. North America Galsulfase (Naglazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. North America Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. North America Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. North America Imiglucerase (Cerezyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. North America Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. North America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. North America Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. North America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. North America Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. North America Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. North America Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. North America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. North America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. North America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. North America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. North America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. North America Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. North America Others - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. North America: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 57. North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 58. US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Growth Strategies in the Glycomic Therapeutics Market (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security